In a comprehensive US administrative database from 2005 to 2008, GLP-1-based treatments, particularly sitagliptin and exenatide, were associated with a significantly increased risk of acute pancreatitis-related hospitalization in adults with T2DM [59], thereby reinforcing prior mechanistic experimental studies and spontaneous reports to the FDA suggesting a potential causal relationship
In addition to dietary changes, incorporating regular physical activity is essential
This integrated anti-inflammatory and anti-fibrotic action complements their metabolic benefits, positioning dual GLP-1 receptor agonists as promising agents in the comprehensive management of MASLD and its complications
On average, the out-of-pocket cost of Ozempic without insurance can range from $800 to $900 for a one-month supply
In: Blanco A, Blanco G, editors